Redirecting to https://investor.seagen.com/press-releases/news-details/2022/Seagen-Announces-U.S.-FDA-Approval-of-New-Indication-for-ADCETRIS-brentuximab-vedotin-for-Children-with-Previously-Untreated-High-Risk-Hodgkin-Lymphoma/default.aspx...

Click here if your browser doesn't automatically take you to this page.